CLAIMS

1. A compound having the formula LiCl*compound **I**, or a solvate or hydrate thereof, wherein compound **I** has the structure:



I.

2. The compound of claim 1, wherein the LiCl*compound **I** is a co-crystal.

3. The compound of claim 1, wherein the lithium and the compound **I** are in a stoichiometric ratio of about 1 to about 1.

4. A pharmaceutical composition comprising the compound according to claim 1 and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

5. The pharmaceutical composition according to claim 4, wherein the composition is formulated for oral administration.

6. The pharmaceutical composition according to claim 4, further comprising an additional therapeutic agent.

7. Use of the compound according to claim 1 or the pharmaceutical composition according to claim 4, in the manufacture of a medicament for treating, preventing, and/or reducing a risk of a disease, disorder, or condition mediated by mTORC1.

8. The use of claim 7, wherein the disease, disorder, or condition mediated by mTORC1 is depression, bipolar disorder, schizophrenia, chronic unpredictable stress, autism, lysosomal storage disease, Batten disease, cystinosis, Fabry disease, mucolipidosis, mental retardation, anorexia, bulimia, anemia, neutropenia, headache, alcoholism, post-traumatic stress disorder

(PTSD), epilepsy, diabetes, liver disease, kidney disorders, arthritis, skin conditions such as seborrhea, overactive thyroid, asthma, Huntington’s disease, Graves' disease, herpes simplex, movement disorders such as tardive dyskinesia, Tourette’s syndrome, cyclical vomiting, Meniere's disease, tingling or crawling sensation in the skin (paresthesias), or aggressive behavior in attention deficit-hyperactivity disorder (ADHD).

9. Use of the compound according to claim 1 or the pharmaceutical composition according to claim 4, in the manufacture of a medicament for treating treatment-resistant depression.

10. Use of the compound according to claim 1 or the pharmaceutical composition according to claim 4, in the manufacture of a medicament for treating major depressive disorder in a patient.

11. The compound according to claim 1 or the pharmaceutical composition according to claim 4, for use in treating, preventing, and/or reducing a risk of a disease, disorder, or condition mediated by mTORC1.

12. The compound or composition for use of claim 11, wherein the disease, disorder, or condition mediated by mTORC1 is depression, bipolar disorder, schizophrenia, chronic unpredictable stress, autism, lysosomal storage disease, Batten disease, cystinosis, Fabry disease, mucolipidosis, mental retardation, anorexia, bulimia, anemia, neutropenia, headache, alcoholism, post-traumatic stress disorder (PTSD), epilepsy, diabetes, liver disease, kidney disorders, arthritis, skin conditions such as seborrhea, overactive thyroid, asthma, Huntington’s disease, Graves' disease, herpes simplex, movement disorders such as tardive dyskinesia, Tourette’s syndrome, cyclical vomiting, Meniere's disease, tingling or crawling sensation in the skin (paresthesias), or aggressive behavior in attention deficit-hyperactivity disorder (ADHD).

13. The compound according to claim 1 or the pharmaceutical composition according to claim 4, for use in treating treatment-resistant depression.

14. The compound according to claim 1 or the pharmaceutical composition according to claim 4, for use in treating major depressive disorder in a patient.

15. The compound according to claim 1 or the pharmaceutical composition according to claim 4, for use in therapy.